NantKwest™ is an innovative clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases.
NantKwest is uniquely positioned to implement precision cancer medicine, with the potential to change the current paradigm of cancer care. Natural Killer cells are ancient cells in the human body designed to recognize and detect cells under stress or infected. The NantKwest “off-the-shelf” activated Natural Killer (NK) platform has the capacity to destroy cancer and virally infected cells from the body. The safety of our NK cells as well as their activity against a broad range of cancers have been tested in multiple phase 1 clinical trials in the United States, Canada and Europe. In addition to our NK cells capability to be administered in the outpatient setting as an “off-the-shelf” living drug, it serves as a universal cell-based therapy without need for individualized patient matching. Moreover, our NK cell based platform has been bioengineered to incorporate chimeric antigen receptors (CARs) and antibody receptors to further optimize targeting and potency in the therapeutic disease.
Natural Killer Cell Platform
NantKwest Announces Successful First in Human Administration of CD16 High Affinity Natural Killer (hank) Cells
Successful Administration Of Off The Shelf Hank Cells In Patients With Solid Tumors Paves The Way To Nation's First Combination Innate And Adaptive NANT Cancer Vaccine Trials In Multiple Tumor Types CULVER CITY, Calif.–October 2, 2017- NantKwest Inc....read more
Nantkwest Builds Financial and Commercial Expertise with the Appointment of Fred Driscoll to its Board of Directors
Culver City, September 22, 2017 - NantKwest, Inc. (Nasdaq:NK) today announced that Fred Driscoll, currently an Advisor and former Chief Financial Officer of Flexion Therapeutics, Inc., has been appointed to the Board to fill the position being vacated by...read more
CULVER CITY, CALIFORNIA-, September 5, 2017 NantKwest (Nasdaq:NK), a leading, clinical-stage natural killer cell based therapeutics company, today announced that the company will be presenting at three investment conference in September. The presentations will feature...read more